Theravance - TBPH Operating Margin

TBPH (theravance.com) - company brandmark

Risks for Theravance Biopharma (TBPH) are linked to royalty volatility and the outcomes of ampreloxetine trials. Strategic alliances with industry behemoths help effectively promote respiratory treatments. The operating profit margin history clearly demonstrates these processes, where the value of 2.10 serves as the current metric. The company's growth potential is based on scalability: the launch of mass production for patented drugs following research promises high returns.

TBPH - theravance.com Operating Profitability over the range 07/04/2022 - 10/10/2026

Analytical breakdowns for Theravance Biopharma (TBPH)

- price and consensus price forecast:
Comprehensive company analysis:theravance.com, TBPH
Core merchandise of Theravance Corp

Investors assess an asset's operational strength through the efficiency of cost management. For Theravance Biopharma (TBPH), royalties and patent protection serve as key factors here, reducing the budgetary burden. Tracking the operating margin allows for the determination of the revenue share remaining after all production and administrative expenses are paid. This percentage reflects the business's actual ability to generate profit before tax deductions. High values confirm the company's resilience to regulatory barriers.

Competitors of Theravance Biopharma

Operating Profitability haleon.com|Operating Profitability KVUE|Operating Profitability Verona Pharma (VRNA)|Jyong Biotech (MENS) - Operating Profitability Margin|Operating Margin LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Operating Profitability|PRGO - Operating Profitability|Alvotech Corp (ALVO) - Operating Sales Margin|LQDA: Operating Margin|Operating Return on Sales glpg.com (GLPG)|Operating Profitability ANI Pharmaceuticals Inc|MNKD: Operating Profit Rate|Operating Sales Margin AMPH (Amphastar)|PCRX - Operating Return on Sales|Operating Margin SPRY (ars-pharma.com)|Operating Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Operating Sales Margin|Operating Return on Sales Tectonic Therapeutic|TNXP: Operating Margin|SXT China (SXTC) - Operating Margin|Operating Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Profitability of Operations|Operating Profitability Invizyne (EXOZ)|ORMP - Operating Return on Sales|Operating Margin ENTX (Entera Bio)|Operating Profitability Margin MindWalk Therapeutics|ABVC: Operating Sales Margin|CPIX - Operating Margin|QNTM (Quantum BioPharma) - Operating Sales Margin|Operating Profit Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Operating Margin|Operating Margin ranitherapeutics.com|Operating Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Return on Sales by Operating Profit|lexariabioscience.com - Operating Sales Margin|Operating Margin Pulmatrix Inc PULM|Pheton Holdings - Operating Margin|Operating Profit Margin APM|Lyra Therapeutics, Inc. (LYRA) - Operating Profitability|Operating Return on Sales Impact BioMedical, Inc. (IBO)|Operating Profitability TNF Pharma|YCBD: Operating Profit Rate|Operating Margin PRFX|CYTO - Operating Return on Sales|Operating Profitability Lipella LIPO|Operating Profit Ratio OPTN (OptiNose, Inc.)|PIRS - Operating Profitability|Procaps (PROC) - Operating Sales Margin|PTPI: Operating Margin|Qilian International (QLI) - Operating Margin|Operating Profitability Acelyrin, Inc.|Operating Margin TFF Pharmaceuticals, Inc.